Difference between revisions of "Finasteride (Proscar)"
Warner-admin (talk | contribs) |
|||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
''No antineoplastic label, at this time.'' | ''No antineoplastic label, at this time.'' | ||
| + | *1992-06-19: Initial approval | ||
==Also known as== | ==Also known as== | ||
Revision as of 13:30, 23 September 2023
General information
Class/mechanism: 5 alpha-reductase inhibitor; inhibits conversion of testosterone to dihydrotestosterone (DHT). Specifically and competitively inhibits Type II 5α-reductase by forming a stable enzyme-drug complex.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
No antineoplastic label, at this time.
- 1992-06-19: Initial approval
Also known as
- Brand name: Proscar